BIOMAT Database Logo BIOMAT Database Logo

[Acute neuropathic (type 2) variant of Gaucher disease with mutation K198E]. 2005

E Espinosa-García, and J C Pérez-Poveda, and O Y Echeverry, and L A Barrera-Avellaneda

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D005776 Gaucher Disease An autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (GLUCOSYLCERAMIDASE) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the MONONUCLEAR PHAGOCYTE SYSTEM. The characteristic Gaucher cells, glycosphingolipid-filled HISTIOCYTES, displace normal cells in BONE MARROW and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement. Cerebroside Lipidosis Syndrome,Gaucher Disease Type 1,Gaucher Disease Type 2,Glucocerebrosidase Deficiency Disease,Glucosylceramide Beta-Glucosidase Deficiency Disease,Neuronopathic Gaucher Disease,Acid beta-Glucosidase Deficiency,Acid beta-Glucosidase Deficiency Disease,Acute Neuronopathic Gaucher Disease,Chronic Gaucher Disease,GBA Deficiency,Gaucher Disease Type 3,Gaucher Disease, Acute Neuronopathic,Gaucher Disease, Acute Neuronopathic Type,Gaucher Disease, Chronic,Gaucher Disease, Chronic Neuronopathic Type,Gaucher Disease, Infantile,Gaucher Disease, Infantile Cerebral,Gaucher Disease, Juvenile,Gaucher Disease, Juvenile and Adult, Cerebral,Gaucher Disease, Neuronopathic,Gaucher Disease, Non-Neuronopathic Form,Gaucher Disease, Noncerebral Juvenile,Gaucher Disease, Subacute Neuronopathic Form,Gaucher Disease, Subacute Neuronopathic Type,Gaucher Disease, Type 1,Gaucher Disease, Type 2,Gaucher Disease, Type 3,Gaucher Disease, Type I,Gaucher Disease, Type II,Gaucher Disease, Type III,Gaucher Splenomegaly,Gaucher Syndrome,Gaucher's Disease,Gauchers Disease,Glucocerebrosidase Deficiency,Glucocerebrosidosis,Glucosyl Cerebroside Lipidosis,Glucosylceramidase Deficiency,Glucosylceramide Beta-Glucosidase Deficiency,Glucosylceramide Lipidosis,Infantile Gaucher Disease,Kerasin Histiocytosis,Kerasin Lipoidosis,Kerasin thesaurismosis,Lipoid Histiocytosis (Kerasin Type),Non-Neuronopathic Gaucher Disease,Subacute Neuronopathic Gaucher Disease,Type 1 Gaucher Disease,Type 2 Gaucher Disease,Type 3 Gaucher Disease,Cerebroside Lipidoses, Glucosyl,Cerebroside Lipidosis Syndromes,Cerebroside Lipidosis, Glucosyl,Deficiencies, GBA,Deficiencies, Glucocerebrosidase,Deficiency Disease, Glucocerebrosidase,Deficiency Diseases, Glucocerebrosidase,Deficiency, GBA,Deficiency, Glucocerebrosidase,Disease, Chronic Gaucher,Disease, Gaucher,Disease, Gaucher's,Disease, Gauchers,Disease, Glucocerebrosidase Deficiency,Disease, Infantile Gaucher,Disease, Juvenile Gaucher,Disease, Neuronopathic Gaucher,Disease, Non-Neuronopathic Gaucher,Diseases, Gauchers,Diseases, Glucocerebrosidase Deficiency,GBA Deficiencies,Gaucher Disease, Non Neuronopathic Form,Gaucher Disease, Non-Neuronopathic,Gauchers Diseases,Glucocerebrosidase Deficiencies,Glucocerebrosidase Deficiency Diseases,Glucocerebrosidoses,Glucosyl Cerebroside Lipidoses,Glucosylceramide Lipidoses,Histiocytoses, Kerasin,Histiocytoses, Lipoid (Kerasin Type),Histiocytosis, Kerasin,Histiocytosis, Lipoid (Kerasin Type),Juvenile Gaucher Disease,Kerasin Histiocytoses,Kerasin Lipoidoses,Kerasin thesaurismoses,Lipidoses, Glucosyl Cerebroside,Lipidoses, Glucosylceramide,Lipidosis Syndrome, Cerebroside,Lipidosis Syndromes, Cerebroside,Lipidosis, Glucosyl Cerebroside,Lipidosis, Glucosylceramide,Lipoid Histiocytoses (Kerasin Type),Lipoidoses, Kerasin,Lipoidosis, Kerasin,Non Neuronopathic Gaucher Disease,Splenomegaly, Gaucher,Syndrome, Cerebroside Lipidosis,Syndrome, Gaucher,Syndromes, Cerebroside Lipidosis,thesaurismoses, Kerasin,thesaurismosis, Kerasin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017809 Fatal Outcome Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept. Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal

Related Publications

E Espinosa-García, and J C Pérez-Poveda, and O Y Echeverry, and L A Barrera-Avellaneda
Mutation screening of 17 Japanese patients with neuropathic Gaucher disease.
August 1996, Human genetics,
E Espinosa-García, and J C Pérez-Poveda, and O Y Echeverry, and L A Barrera-Avellaneda
Intrauterine onset of acute neuropathic type 2 Gaucher disease: identification of a novel insertion sequence.
July 2004, American journal of medical genetics. Part A,
E Espinosa-García, and J C Pérez-Poveda, and O Y Echeverry, and L A Barrera-Avellaneda
Neuropathic Gaucher disease.
December 2010, Wiener medizinische Wochenschrift (1946),
E Espinosa-García, and J C Pérez-Poveda, and O Y Echeverry, and L A Barrera-Avellaneda
Novel point mutation (W184R) in neonatal type 2 Gaucher disease.
January 2000, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society,
E Espinosa-García, and J C Pérez-Poveda, and O Y Echeverry, and L A Barrera-Avellaneda
Acute neuropathic Gaucher disease in a black infant.
November 1978, The Journal of pediatrics,
E Espinosa-García, and J C Pérez-Poveda, and O Y Echeverry, and L A Barrera-Avellaneda
Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease.
June 1991, FEBS letters,
E Espinosa-García, and J C Pérez-Poveda, and O Y Echeverry, and L A Barrera-Avellaneda
Acute neuronopathic (type 2) Gaucher disease in siblings in southern Thailand.
February 1985, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
E Espinosa-García, and J C Pérez-Poveda, and O Y Echeverry, and L A Barrera-Avellaneda
Identification of a new mutation (P178S) in an African-American patient with type 2 Gaucher disease.
January 1995, Human mutation,
E Espinosa-García, and J C Pérez-Poveda, and O Y Echeverry, and L A Barrera-Avellaneda
Gaucher disease: enzyme therapy in the acute neuronopathic variant.
July 1997, American journal of medical genetics,
E Espinosa-García, and J C Pérez-Poveda, and O Y Echeverry, and L A Barrera-Avellaneda
Surgery for gastroesophageal reflux disease with Gaucher disease type 2.
July 2016, Pediatrics international : official journal of the Japan Pediatric Society,
Copied contents to your clipboard!